NLINKN1 Chip+PRIME.StudySYNCRStentrode+$75M.SeriesDPRECNLayer 7+FDA.BrkthruPARAMArgo+$20M.SeriesBBLKRKNeuroport+200.ImplantsEMTIVMN8+$45M.SeriesBKRNLFlux+Non-invasiveNRBLEHalo+Consumer.BCINEURONeuroPace+RNS.SystemCOGNICognixion+ALS.TrialFUND.YTD2026$2.8B.SectorTRIALSActive50+.ClinTrialsIMPLNTSHumans~100.Intracrtnl
endovascularbreakthroughinvestigational

Stentrode

Implant Type
endovascular
Electrodes
16
Channels
16
FDA Status
breakthrough
Clinical Stage
SWITCH US / COMMAND pivotal trial
Status
investigational
About

The Stentrode is the world's only endovascular brain-computer interface, implanted via a minimally invasive catheter procedure through the jugular vein into the superior sagittal sinus — a large blood vessel running along the top of the brain. No open brain surgery is required. Once deployed, the self-expanding nitinol stent-electrode array conforms to the vessel wall adjacent to the motor cortex, recording local field potentials and action potentials through the vessel wall. Signals are transmitted subcutaneously to a chest-mounted Investigational Transmitter Device (ITD). The system received FDA Breakthrough Device Designation in 2020 and has been implanted in over 10 patients across the US and Australia.

Target Conditions
ALSmotor neuron diseaselocked-in syndromestroke
Milestones
2019-04First human implant in Melbourne, Australia
2020-08FDA Breakthrough Device Designation granted
2021-07SWITCH Australia feasibility study completed (4 patients)
2022-07First US patient implanted at Mount Sinai, New York
2023-01US patient sends Twitter post using thought alone
2024-06COMMAND pivotal trial initiated
FDA Regulatory Pathway
Breakthrough Device Designation

FDA Breakthrough Device Designation provides more interactive communication with FDA during development and a priority review pathway. The device is still under investigation and not yet approved for commercial sale.

FDA Device Regulatory Guidance ↗